2SELLERS D J, MCKAY N. Developments in the pharmacotherapy of the overaetivebladder[J].Curr Opin Urol, 2007,17(4):223-230.
3osAMu Y, OSAMU N, MASAYUKI T, et al. Clinical guidelines for overactive bladder[J]. Int J Urol, 2009,16:126-142.
4SCHWINN DA, MICHEBTTI GA. Alphal-adrenergic receptors in the lower urinary tract and vascular bed:potential role for the alphald subtype in filling symptoms and effects of ageing on vascular expression [J], BJU Int, 2000,85 (Suppl2) : 6-11.
5NELSON CP, GUPTA P, NAPIER C M, etal. Functional selectivity of muscarinic receptor antagonists for inhibition of M3- mediated phosphoinostide responses in guinea pig urinary bladder andsubmandibular salivary gland[J]. J Pharmacol Exp Ther, 2004,310(3) :1255-1265.
6CHAPPLE CR. Darifenaein: a novel M3-muscarinic selective receptor antagonist for the treatment of overactive bladder[J]. Expert Opin Investig Drugs, 2004,13(11) : 1493-1500.
2Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome: Overactive Bladder Symptom Score [J]. Urology, 2006, 68: 318-323.
3Wein A J, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis and management [J]. Urol, 2006, 175: 5-10.
4Milsom I, Stewart W, Thuroff J. The prevalence of overactive blad- der. Am J Manag Care ,2006,11 (Suppl) : s565-s573.
5Killeher C J, Cardozo L, Chapple CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifena- cin. BJU Int,2005,95 (1) :81-85.
6Chapple CR. Darifenacin:a novel M3 muscarinic selective recep- tor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs ,2006,13 ( 11 ) : 1493-1500.
7Sexton CC,Notte SM,Maroulis C,et al. Persistence and adherence in treatment of overactivebladder syndrome with anticholinergic therapy:a systematic review of the literature[J]. Int J Clin Pract,2011,65(5):567-585.
8Abrams P,Cardozo L,Fall M,et al. The standardisation of terminologyof lower urinary tract function: report from the StandardisationSub-committee of the International Continence Society[J]. Neurourol Urodyn,2002,21(2):167-168.
9Wang Y,Xu K,Hu H,et al. Prevalence, risk factors,and impact on health related quality of life of overactivebladder in China[J]. Neurourol Urodyn,2011,30(8):1448-1455.
10Kollef MH. Avoidance of tracheal intubation as a strategy to pre-vent ventilator-associated pneumonia[J]. Intensive Care Med,2010,25(6):553-555.
